Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127029652 | 12702965 | 2 | F | 2010 | 20160907 | 20160831 | 20160915 | EXP | CN-GLAXOSMITHKLINE-CN2016GSK124308 | GLAXOSMITHKLINE | 55.00 | YR | M | Y | 58.00000 | KG | 20160915 | CN | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127029652 | 12702965 | 1 | PS | HEPTODIN | LAMIVUDINE | 1 | Oral | 300 MG, QD | Y | 21003 | 300 | MG | TABLET | QD | |||||
| 127029652 | 12702965 | 2 | SS | HEPTODIN | LAMIVUDINE | 1 | 1 DF, QD | Y | 21003 | 1 | DF | TABLET | QD | ||||||
| 127029652 | 12702965 | 3 | SS | LAMIVUDINE. | LAMIVUDINE | 1 | UNK | Y | 0 | ||||||||||
| 127029652 | 12702965 | 4 | SS | SIROLIMUS. | SIROLIMUS | 1 | Oral | UNK | 0 | TABLET | |||||||||
| 127029652 | 12702965 | 5 | SS | CELLCEPT | MYCOPHENOLATE MOFETILMYCOPHENOLATE MOFETIL HYDROCHLORIDE | 1 | Oral | UNK | 0 | TABLET | |||||||||
| 127029652 | 12702965 | 6 | SS | TACROLIMUS. | TACROLIMUS | 1 | Oral | UNK | 0 | CAPSULE | |||||||||
| 127029652 | 12702965 | 7 | SS | YIN QIAO | HERBALS | 1 | UNK | U | 0 | TABLET | |||||||||
| 127029652 | 12702965 | 8 | SS | CONTAC NT (CHLORPHENIR+DEXTROMETHORPHAN+PARACETAMOL+PSEUDOEPHEDRINE) | ACETAMINOPHENCHLORPHENIRAMINE MALEATEDEXTROMETHORPHANPSEUDOEPHEDRINE | 1 | 1 DF, QD | U | 0 | 1 | DF | TABLET | QD | ||||||
| 127029652 | 12702965 | 9 | SS | CEPHALOSPORIN | UNSPECIFIED INGREDIENT | 1 | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127029652 | 12702965 | 1 | Hepatitis B |
| 127029652 | 12702965 | 3 | Hepatitis B |
| 127029652 | 12702965 | 4 | Transplant rejection |
| 127029652 | 12702965 | 5 | Transplant rejection |
| 127029652 | 12702965 | 6 | Transplant rejection |
| 127029652 | 12702965 | 7 | Nasopharyngitis |
| 127029652 | 12702965 | 8 | Nasopharyngitis |
| 127029652 | 12702965 | 9 | Nasopharyngitis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127029652 | 12702965 | HO |
| 127029652 | 12702965 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127029652 | 12702965 | Blood creatinine increased | |
| 127029652 | 12702965 | Hepatitis B DNA increased | |
| 127029652 | 12702965 | Nasopharyngitis | |
| 127029652 | 12702965 | Product availability issue | |
| 127029652 | 12702965 | Pyrexia | |
| 127029652 | 12702965 | Renal impairment | |
| 127029652 | 12702965 | Renal transplant |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127029652 | 12702965 | 1 | 2010 | 2014 | 0 | |
| 127029652 | 12702965 | 3 | 2014 | 2014 | 0 | |
| 127029652 | 12702965 | 4 | 2013 | 0 | ||
| 127029652 | 12702965 | 5 | 2013 | 0 | ||
| 127029652 | 12702965 | 6 | 2013 | 0 | ||
| 127029652 | 12702965 | 7 | 20160905 | 0 | ||
| 127029652 | 12702965 | 8 | 20160905 | 0 | ||
| 127029652 | 12702965 | 9 | 20160905 | 0 |